Annual Results: The net sales increased by 179.98 per cent to Rs 643.79 crore, the operating profit increased by 91.67 per cent to Rs 211.74 crore and the net profit increased by 153.5 per cent to Rs 109.63 crore in FY23 compared to FY22.

Previously, the company emerged as the winner in the Gujarat Urja Vikas Nigam Limited (GUVNL) tender for the development of the Solar Photovoltaic Power Project. The aggregate order size is 200 MW AC (240 MW P)

The stock has witnessed significant buying activity surging more than 70 per cent in the last 1 year. 

Shares of the company have gained more than 35 per cent in the last six months.

In H2FY23, the company reported net sales of Rs 20.29 crore compared to net sales of Rs 23.32 crore in H2FY22. The net sales increased by 41.57 per cent to Rs 1.26 crore in H2FY23 over H2FY22. In FY23, the net profit increased by 66 per cent to Rs 1.66 crore compared to 1 crore in FY22.

The company has a market cap of over Rs 1,300 crore with a 5-year stock price CAGR of 92 per cent. The shares of the company saw a spurt in volume by more than 1.39 times on BSE.

Shares of the company have gained more than 60 per cent in the last six months.

The stock has witnessed significant buying activity surging more than 626 per cent in the last 3 years. 

Shares of the company have gained more than 150 per cent in the last one year.

hese grants are earmarked for endeavors in the realm of Tuberculosis (TB) and Human Papillomavirus (HPV) tests on the innovative Co-DX PCR Home platform. The intention behind these grants is to enable the completion of these vital tests, geared toward vital global markets, where the prevalence of these conditions is pronounced.

The company also recorded an 82 per cent growth in net profit for the June quarter.